Valuable Updates on Pharmaceutical Companies: New Research on Avalanche Biotechnologies, BioCryst, Biogen, Biota Pharmaceuticals, and Bio-Techne
NEW YORK, February 10, 2015 /PRNewswire/ --
Editor Note: For more information about this release, please scroll to bottom.
Moments ago, Analysts Review released new research updates concerning several important developing situations including Avalanche Biotechnologies (NASDAQ: AAVL), BioCryst (NASDAQ: BCRX), Biogen (NASDAQ: BIIB), Biota Pharmaceuticals (NASDAQ: BOTA), and Bio-Techne (NASDAQ: TECH). Analysts Review provides a single unified platform for investors' to hear about what matters - proudly employing registered CFA® research staff and rigorous compliance procedures. The full research reports are being made available to the public for informational purposes only.
To access our full PDF reports on a complementary basis, please visit the links below.
--
Today's update concerns the following companies:
============
Full PDF Download Links (you may have to copy and paste the following links into your browser):
AAVL Research Report: ( http://get.analystsreview.com/pdf/?c=Avalanche%20Biotechnologies&d=10-Feb-2015&s=AAVL ),
BCRX Research Report: ( http://get.analystsreview.com/pdf/?c=BioCryst&d=10-Feb-2015&s=BCRX ),
BIIB Research Report: ( http://get.analystsreview.com/pdf/?c=Biogen&d=10-Feb-2015&s=BIIB ),
BOTA Research Report: ( http://get.analystsreview.com/pdf/?c=Biota%20Pharmaceuticals&d=10-Feb-2015&s=BOTA ),
TECH Research Report: ( http://get.analystsreview.com/pdf/?c=Bio-Techne&d=10-Feb-2015&s=TECH ).
============
--
Analyst Update: Quarterly Earnings, Fast Track Designations, and Scheduled Events
Reviewed by: Rohit Tuli, CFA®
The U.S. stocks ended lower on Monday as investors fled to safe-haven assets amid a worsening standoff between the Greece's new government and its creditors. Greece's Prime Minister Alexis Tsipras refused to accept any extension of the country's international bailout and also announced plans to cancel some of the reforms imposed by the lenders, raising fears of a fresh crisis in the euro zone. The Dow Jones Industrial Average ended the session lower by 0.53% at 17,729.21, the S&P 500 declined 0.42% to close at 2,046.74, and the Nasdaq Composite finished lower by 0.39% at 4,726.01. In Europe, the Stoxx 600 index fell for the first time in six days amid uncertainty looming over Greece's debt negotiations. Meanwhile, Asian markets ended mostly lower on Monday as worries over Greece were compounded by disappointing Chinese trade data. A latest data showed that Chinese exports unexpectedly fell 3.3% in January, compared with the year ago period, while imports dropped 19.9%.
Avalanche Biotechnologies, Inc. (Avalanche Biotechnologies) posted Q3 2014 revenue of $0.2 million versus $30,000 during Q3 2013. For the quarter, research and development expenses were $5.7 million, compared to $0.6 million during Q3 2013. The Company reported net loss of $8.3 million versus a net loss of $0.8 million during Q3 2013.
BioCryst Pharmaceuticals, Inc. (BioCryst) announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for its BCX4161, a novel, orally administered, selective inhibitor of plasma kallikrein in advanced clinical development for the treatment of hereditary angioedema.
Biogen Idec Inc.'s (Biogen) 2014 revenue increased 40% YoY to $9.7 billion. The gains continued in bottom-line as well, as net income surged 58% YoY to $2.9 billion. Diluted EPS for 2014 stood at $12.37, compared with $7.81 in 2013. For 2015, the Company expects revenue growth to be approximately 14% to 16% YoY and EPS to range between $15.45 and $15.85.
Biota Pharmaceuticals, Inc. (Biota Pharmaceuticals) is scheduled to make a presentation at the 2015 BIO CEO & Investor Conference. Biota Pharmaceuticals' CEO & President Joseph Patti will present a corporate overview on Tuesday, February 10, 2015 at 3:00 p.m. EST at the Waldorf Astoria Hotel in New York.
Bio-Techne Corp (Bio-Techne) announced solid Q2 FY 2015 financial results. Revenue increased 33% YoY to $111.9 million, net earnings stood at $33.2 million or $0.89 per diluted share, compared to $25.1 million or $0.68 per diluted share in Q2 FY 2014.
--
About Analysts Review
At Analysts Review, we provide our members with a simple and reliable way to leverage our economy of scale. Most investors do not have time to track all publicly traded companies, much less perform an in-depth review and analysis of the complexities contained in each situation. That's where Analysts Review comes in. We provide a single unified platform for investors' to hear about what matters. Situation alerts, moving events, and upcoming opportunities.
Analysts Review was designed for investors. By providing the best information available, we have set ourselves apart as one of the premier online investor communities.
--
Editor Note: This is not company news. We are an independent source and our views do not reflect the companies mentioned.
Compliance Procedure: Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA®. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
Further Resources: For more information about this release including editorial notes, compliance procedures and legal disclosures, please visit: http://www.analystsreview.com/editors
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Analysts Review
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article